ClinicalTrials.gg
Sign In
Not yet recruitingNCT07596537Updated May 20, 2026

The Effect of Detrusor Underactivity in Determining Outcomes After Transurethral Resection of the Prostate for Treatment of Benign Prostatic Hyperplasia

An interventional study of transurethral resection of Prostate in Detrusor Underactivity and Transurethral Resection of the Prostate (TURP), sponsored by Ain Shams University. Not yet recruiting. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
50 Years and older
Sex
Male
01

Study summary

The aim of this clinical trial is to evaluate the effect of detrusor underactivity on the functional and symptomatic outcomes following transurethral resection of the prostate (TURP) in benign prostatic hyperplasia patients presenting with chronic urinary retention.

The main questions it aims to answer are:

Will they restore spontaneous voiding?

They will be divided into 2 comparative groups (each group 45 patients) based on detrusor contractility.

  • Group (A) consists of patients with normal detrusor (bladder contractility index more than 100).
  • Group (B) consists of patients with underactive detrusor (bladder contractility index less than 100).
02

Conditions studied

  • Detrusor Underactivity
  • Transurethral Resection of the Prostate (TURP)
03

In context

Urinary Bladder, Underactive

31 studies on the registry are indexed under Urinary Bladder, Underactive; 6 are open to participants now.

This study's planned enrollment of 90 is above the median of 66 across 21 interventional studies indexed under Urinary Bladder, Underactive.

Browse Urinary Bladder, Underactive studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,950 studies on the registry; 429 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Ain Shams University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: more than 50-year-old
  • Chronic urinary retention secondary to BPH
  • Prostate size Above 30 and less than 100gm

Exclusion criteria

Exclusion Criteria:

  • Prostate size over 100 gm and less than 30 gm
  • Prostatic carcinoma
  • Urinary bladder carcinoma
  • Acute urinary retention
  • Urethral stricture.
  • Previous bladder, urethral or prostate surgery.
  • Acute urinary tract infection.
  • Neurogenic bladder
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    consists of patients with underactive detrusor (bladder contractility index less than 100).

    • Group (B) - Underactive Detrusor

    Procedure: transurethral resection of Prostate

  • Active comparator
    consists of patients with normal detrusor (bladder contractility index more than 100).

    • Group (A) - Normal detrusor

    Procedure: transurethral resection of Prostate

Interventions

  • Proceduretransurethral resection of Prostate

    Standard TURP

06

What researchers measure

Primary outcomes

  1. Restore spontaneous voiding

    All the included patients in this study are urethral catheter-dependant pre-operatively and have very bad voiding parameters. we will assess how they will benefit after TURP by regaining spontaneous voiding without the need for urethral catheters any more.

    Time frame: 3 months

Secondary outcomes

  1. Flow rate improvement

    uroflowmetry will be done to all patients 3 months post operative and results will be compared

    Time frame: 3 months

  2. Post voiding residual urine volume decrease

    Post voiding residual urine volume will be calculated using ultrasound and results will be compared

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Dec 2026, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 19, 2026
StartEst.
May 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07596537
Lead sponsor
Ain Shams University
Responsible party
samir sherif (Principal Investigator, Ain Shams University) — Principal investigator
First posted
May 19, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
May 20, 2026

Study contacts

Samir Sherif Rizkallah, MBBCH
Contact
150278@med.asu.edu.eg
+201226846005

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Urinary Bladder, Underactive →

Other studies from this sponsor

Ain Shams University →

Start the discussion